
zzso is a zzso zzso proposed for clinical trials on the basis of a broad spectrum of activity against zzso tumors and a reduced potential for toxic manifestations at the injection site as compared to the parent zzso This phase I trial was designed to define the maximum tolerated dose of zzso given by zzso zzso on a zzso zzso zzso adult patients with a variety of solid tumors were zzso Their median performance status was 2 zzso zzso and most had received prior zzso chemotherapy, or zzso A median of one course zzso one to four) was zzso for a total of 47 zzso zzso were escalated from 6 to 250 zzso zzso and zzso were zzso and zzso with a strong suggestion of increased zzso with repeated zzso zzso toxic effects were generally mild to zzso zzso and vomiting were experienced by most zzso Local toxic effects consisting of zzso zzso zzso and/or zzso were encountered in about one-half of the zzso zzso drug-related zzso in liver function were noted in three zzso zzso zzso and fatigue were also zzso zzso effect was detected in one patient with zzso of unknown zzso A dose of 200 zzso for 5 consecutive days may be recommended for phase II zzso 

